Following NCPE assessment of daratumumab (Darzalex®) monotherapy, it is not considered cost-effective and therefore is not recommended for reimbursement.

Following NCPE assessment of mepolizumab (Nucala®) it is not considered cost-effective and therefore is not recommended for reimbursement at the submitted price.

Following NCPE assessment of the applicant’s submission, Obinutuzumab (Gazyvaro®) is not considered cost-effective at the submitted price.

The NCPE does not consider cobimetinib (Cotellic®) with vemurafenib (Zelboraf®) cost-effective for the treatment of advanced (unresectable or metastatic) melanoma with the BRAF V600 mutation and therefore it is not recommended for reimbursement at the submitted price.

The cost-effectiveness of human alpha-1 proteinase inhibitor (Respreeza®) has not been demonstrated and therefore is not recommended for reimbursement.

The cost effectiveness of elosulfase alfa (Vimizim®) has not been demonstrated. Therefore it is not recommended for reimbursement

The NCPE does not consider Vortioxetine (Brintellix®) cost-effective for the treatment of major depressive disorder in adults and therefore is not recommended for reimbursement.

The NCPE does not consider nivolumab (Opdivo®) with ipilimumab (Yervoy®) cost-effective for the treatment of advanced (unresectable or metastatic) melanoma and therefore is not recommended for reimbursement at the submitted price.

Following review the NCPE recommends that ivacaftor should not be reimbursed for this indication at the submitted price.

Following review of the company submission, the NCPE do not consider nivolumab to be cost-effective at the submitted price.